About us
- - - About us
      
      COMPASS Pathways is a mental health care company. We are dedicated to accelerating patient access to evidence-based innovation in mental health.
  - - About us
    - Our team
  - - Annual Review 2021
      
      In 2021 we took a giant leap forward in our work to transform mental health care.
      
      Read about our progress
Our work
- - - Our work
      
      We want to find better ways to support people suffering with mental health challenges, and we believe we’re onto something important.
  - - Our publications and results
    - Our approach
  - - COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
      
      Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological treatment option.
      
      Read more
Join us
- - - Join us
      
      Here at COMPASS, we are united by our commitment to improving patient experience and outcomes in mental health care.
  - - Join us
  - - Our graduate programme
      
      We are launching a graduate programme in Research and Development, which will offer life science graduates the opportunity to kickstart a career at COMPASS.
      
      Find out more
News & views
- - - News & views
      
      Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
  - - All news & views
  - - COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
      
      Kabir Nath will build upon COMPASS’ success and lead the development of novel models of care to accelerate patient access to evidence-based innovation in mental health care
      
      Read more
Investors
- - - Investors
      
      We are COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
  - - News & events
    - Stock information
  - - Corporate governance
    - Investor resources
  - - COMP360 psilocybin therapy in TRD
      
      We have completed the largest randomised, controlled, double-blind psilocybin therapy study ever done.
      
      Read more
Responsibility
- - - Responsibility
      
      We are building a sustainable business that supports patients, health systems, and society in a way that reflects our values.
  - - Responsibility
  - - About us
      
      We have put a lot of thought into the kind of organisation we want to be, and make every decision with our four values in mind.
      
      Read more
LinkedIn
Youtube
Accessibility

Accessibility options

High Contrast
Greyscale
Negative Contrast
Readable
Reset

Search for news

News & views

Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.

Search for news

All news & views
COMPASS news
Our perspectives
Our stories
COMPASS news archive

White Paper 2021

Our White Paper looks at the state of mental health care in the US, with a focus on treatment-resistant depression.

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020

COMPASS Pathways News | December 2020 Issue

Our highlights in the second half of 2020 as we work towards building a world of mental wellbeing for everyone.

« Previous 1 2

Home
Articles
COMPASS news
Page 2

This website is powered by renewable energy

Useful links

Contact us
Our results
About psilocybin therapy
About us
Join us
News & views
Annual Review 2021

LinkedIn
Youtube

Unsolicited Information Policy
Terms
Privacy
myPathfinder privacy

The press releases and articles contained in this section are provided for historical purposes only. The information contained in each press release and article is accurate only as of the date each press release and article was originally issued. COMPASS disavows any obligation to update the information contained in such press releases and articles after the date of their issuance.

You are now leaving COMPASS Pathways’ website.

COMPASS does not control and is not responsible for the content on the website you are about to visit. COMPASS is providing this link as a convenience, and this link does not imply COMPASS endorsement of any material on the website you are about to visit. Do you wish to continue?

This site uses functional cookies and external scripts to improve your experience.

Privacy settings

Privacy Settings

This site uses functional cookies and external scripts to improve your experience. Which cookies and scripts are used and how they impact your visit is specified on the left. You may change your settings at any time. Your choices will not impact your visit.

NOTE: These settings will only apply to the browser and device you are currently using.

More Information

If you would like to know more about Cookie Notices and Cookie Consent click here

Functional

These cookies are required for basic site functionality and are therefore always enabled. These include cookies that allow you to be remembered as you explore the site within a single session or, if you request, from session to session. They help make the shopping cart and checkout process possible as well as assist in security issues and conforming to regulations.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but if you do so, some parts of the site will not work. These cookies do not store any personal information.

About us

Annual Review 2021

Our work

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Join us

Our graduate programme

News & views

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Investors

COMP360 psilocybin therapy in TRD

Responsibility

About us

News & views

Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.